Sunday, November 22, 2026

Private Credit Equity Cure Rights: How Covenant Fixes Work

Share

Opening: A Cure Is a Contract Right, Not a Business Recovery

An equity cure right gives a borrower’s owner, often a private equity sponsor, a limited opportunity to address a breach of a financial covenant by contributing new cash. It can keep a temporary earnings shortfall from becoming an immediate event of default. It does not, by itself, restore customers, margins, or operating cash flow.

For a private credit borrower, a covenant breach can trigger lender remedies even when scheduled interest and principal are current. A cure provision creates a defined alternative: the owner injects capital, and the loan agreement permits that contribution to affect the covenant calculation. The exact result depends on the wording. Some agreements treat the contribution as additional EBITDA for the test; others require it to reduce debt, or specify a different formula.

The distinction matters to both sides. Investors need to know whether a reported pass reflects stronger operations or sponsor cash. Operators need to know the cash cost, deadline, and remaining options before signing a term sheet. A cure is a bridge, not forgiveness of the underlying credit problem.

The Concept: How an Equity Cure Works

A financial covenant is a contractual test of a borrower’s financial condition. A common example is maximum total leverage, calculated as debt divided by earnings before interest, taxes, depreciation, and amortization (EBITDA). If the agreement caps leverage at a stated multiple, falling EBITDA can cause a breach even if the loan balance has not increased.

An equity cure allows the sponsor or another permitted owner to contribute cash within a specified cure period after the borrower delivers its compliance certificate or identifies the breach. Under an EBITDA-based cure, the agreement may let the borrower add some or all of that contribution to EBITDA solely for the covenant calculation. Under a debt-paydown cure, contributed cash is applied to reduce debt, improving the ratio’s numerator. The documents define eligible contributors, timing, permitted application, and calculation details.

Most provisions also set boundaries. These may include a maximum number of cures over the life of the loan or during consecutive test periods, a cap on total cure amounts, and a rule that cure proceeds cannot be counted as EBITDA for other purposes. An equity cure typically does not erase unpaid interest, waive unrelated covenant breaches, or change the loan’s maturity. It changes the contractual test only as the documents allow.

How It Works: A Numerical Example

Assume a company has $100 million of debt and trailing-twelve-month EBITDA of $20 million. Its leverage is 5.0x. The credit agreement sets a maximum leverage covenant of 4.75x. The company misses the test after EBITDA falls, although it has made every scheduled interest payment.

Suppose the agreement permits a sponsor contribution to be treated as additional EBITDA for the leverage test. To pass at $100 million of debt, covenant EBITDA must equal at least $21.05 million: $100 million divided by 4.75. The company therefore needs about $1.05 million of permitted EBITDA credit, assuming the agreement allows each contributed dollar to count dollar-for-dollar and no other adjustments apply. A $1.1 million qualifying contribution would produce adjusted covenant EBITDA of $21.1 million and leverage of about 4.74x.

The accounting and economic reality remain different. Operating EBITDA is still $20 million. The sponsor has supplied $1.1 million in cash, and the company has passed one test under a contractual adjustment. If the covenant is tested quarterly, the next test may fail again unless performance improves or another cure is available. A debt-paydown formulation would require a different calculation: to reach 4.75x with $20 million EBITDA, debt must be no more than $95 million, implying a $5 million paydown.

That is why a lender reviews more than the cure amount. It checks whether proceeds must be used to repay debt, whether the cure raises covenant EBITDA only, whether the adjustment flows into other ratios, and whether repeated cures are allowed. A clause that supplies temporary headroom is not equivalent to a permanent amendment or a waiver.

Current Market Relevance

The latest available indicators show why cure language deserves close reading, even when overall loan performance is not captured by one headline number. According to the Federal Reserve’s October 2026 SLOOS, released November 2, 2026, standards for commercial and industrial loans to large and middle-market firms were basically unchanged in the third quarter of 2026, while banks tightened standards for small firms. The Fed also reported tighter premiums on riskier loans for firms of all sizes (survey period: Q3 2026).

Pricing for private loans also moved. Goodwin’s November 19, 2026 Debt Download, citing PitchBook LCD’s October monitor, reported that direct-lending LBO spreads averaged 520 basis points in Q3 2026, compared with 494 basis points in Q2 and 475 basis points in Q1. Nearly three-quarters of Q3 LBOs priced at 500 basis points or wider, versus about one-fifth in Q1. These are Q3 2026 deal measures, not a live quote for a new borrower.

Documentation and leverage provide further context. Goodwin’s November 19 summary of Q3 Covenant Review data reported private-credit LBO debt at 4.0x first-lien and total debt to pro forma EBITDA, compared with 5.1x first-lien and 5.3x total debt for broadly syndicated loan LBOs. Separately, Proskauer’s October 27, 2026 Q3 Private Credit Default Index recorded a 2.41% default rate for July 1 through September 30, down from 2.51% in Q2; its sample covered 746 loans and $205.7 billion in original principal. These figures describe different samples and measures. They do not establish that any particular borrower will need a cure.

Decision Framework: Investors and Operators

For investors evaluating a loan, start with the math and the triggers. Identify the covenant tested, headroom at closing, testing frequency, cure notice deadline, and maximum amount and frequency of permitted cures. Determine whether sponsor cash is applied to debt or added to covenant EBITDA. Check whether the adjustment is isolated to that covenant or also affects pricing, baskets, additional debt capacity, or other ratios. Ask how the lender receives evidence of funding and whether cure rights can be exercised in consecutive quarters. Track cured tests separately from tests passed through operating results.

For operators considering a financing, model a downturn before accepting the clause as protection. Estimate the cash injection needed at several EBITDA levels, then compare it with sponsor liquidity and competing uses of capital. Clarify the cure window, funding mechanics, and whether cash must be paid directly to the lender. Ask what happens after a cure, including whether the next quarter has a tighter test or whether the cure count is exhausted. If the business forecast depends on repeated sponsor contributions, renegotiating covenant levels or adding equity may be more durable than relying on a limited cure provision.

For both parties, separate covenant compliance from solvency and debt service. A cure can prevent a technical default for the defined test, but it does not prove that the borrower can cover interest, fund working capital, or repay at maturity. The provision is most useful when a short-lived disruption is plausible and the owner has committed, available capital. It is less protective when a recurring operating shortfall is being masked by adjustments.

Key Takeaways

  • An equity cure is a contractual remedy with defined limits, not an automatic waiver or proof of operating recovery.
  • Read whether contributed cash increases covenant EBITDA, pays down debt, or follows another specified formula.
  • Calculate the cash needed to pass the test and verify the deadline, cure cap, and frequency restrictions.
  • Investors should distinguish sponsor-funded covenant headroom from performance-generated headroom.
  • Operators should model the next test as well as the current breach, because a one-quarter cure may defer rather than solve the problem.

Disclaimer: Please remember that past performance may not be indicative of future results.

bond CAPITAL Research
bond CAPITAL Research
bond CAPITAL Research is the research desk of bond CAPITAL, covering private credit, interest rates and capital-stack structuring. It publishes daily analysis across five topic areas, from private credit fundamentals to risk management and underwriting.

Read more

Local News